title: Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment.
abstract: The effect of cholecalciferol and estrogen-norethindrone treatment on total cholesterol level, high-density lipoprotein cholesterol level, blood pressure, and body mass index was investigated in 74 postmenopausal women in a double-blind, randomized trial. Blood pressure and body mass index did not change throughout the study. We demonstrated a decrease (11%) in serum cholesterol level after 1 year of treatment with estrogen-norethindrone. When this treatment was combined with cholecalciferol, a similar decrease (13%) was observed. The hypocholesterolemic effect was correlated to body mass index in a way that indicated the most pronounced decrease in lean women. The high-density lipoprotein cholesterol/total cholesterol fraction increased by 45% after 1 year of estrogen-norethindrone treatment, while an increase of 25% after 1 year was seen when cholecalciferol was added to the treatment. The latter increase was not different from a similar increase in the placebo group. The possible dyslipidemic effect of cholecalciferol, along with the risk of hypercalcemia, emphasizes the caution necessary in cholecalciferol treatment.
authors.affiliation: Department of Clinical Chemistry, Frederiksberg Hospital, Copenhagen, Denmark.
authors.forename: B
authors.initials: B
authors.lastname: Myrup
authors.forename: G F
authors.initials: GF
authors.lastname: Jensen
authors.forename: P
authors.initials: P
authors.lastname: McNair
mesh_terms: D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D002762:Cholecalciferol / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects*; D003718:Denmark / Q000453:epidemiology; D004311:Double-Blind Method; D004338:Drug Combinations; D004958:Estradiol / Q000627:therapeutic use*; D004964:Estriol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D009640:Norethindrone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors
chemical_list: D008076:Cholesterol, HDL; D004338:Drug Combinations; D002762:Cholecalciferol; D004958:Estradiol; C032040:Trisequens; D002784:Cholesterol; D004964:Estriol; D009640:Norethindrone